PISCATAWAY, NJ, March 8, 2013 (GLOBE NEWSWIRE) -- InnoPharma, Inc. today announced the launch of cidofovir injection (generic equivalent of Vistide®) in 5mL single-use vials. InnoPharma developed the generic formulation of cidofovir, which will be marketed in the United States by Mylan, Inc. (NASDAQ: MYL). Cidofovir injection is indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). For more information regarding this product, including its black box warning, please refer to the Mylan website at www.mylan.com.
